Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing novel treatments for inflammatory lung diseases and cancer.
Cantex’s pipeline consists of two product candidates – Dicopp® and DSTAT. Both drugs are in clinical development for diseases where innovative and more effective treatments are greatly needed.
Dicopp®, which is a proprietary combination of disulfiram + copper, is being developed for the treatment of long-term as well as short-term complications of COVID-19 infection. A Phase 2 study of Dicopp® as a treatment of the prolonged disabling complications of COVID-19 infection commonly known as “long-haul COVID-19”, as well as in the treatment of recently infected patients with mild to moderate symptoms of COVID-19 infection is expected to begin in 2021. In addition, Dicopp® will begin a trial in relapsed/refractory myeloma in early 2021.
DSTAT, licensed to Chimerix in July 2019, is being studied in two disease indications: COVID-19-associated acute lung injury (ALI) and acute myeloid leukemia (AML). Cantex remains involved in the continued development of DSTAT via a Joint Development Committee. In COVID-19 associated ALI, DSTAT is currently the subject of an ongoing Phase 2/3 clinical trial. DSTAT is also being studied as a potential treatment for AML. A randomized Phase 2 clinical trial in AML indicated that DSTAT + “7+3” improves event-free and relapse-free survival as well as overall survival without additive toxicity. A Phase 3 clinical trial in AML will begin in early 2021.